Mitapivat is the first disease-modifying pharmacotherapy shown to have beneficial effects on iron overload in adult patients with PK deficiency through its multimodal action, including modulating the erythroferrone–hepcidin axis. The gene discussed is HAMP; the disease is pyruvate kinase deficiency of red cells.